Planning for and Managing FDA Inspections. Focus: 21 CFR, Part 820
|
|
- Dina Douglas
- 7 years ago
- Views:
Transcription
1 Planning for and Managing FDA Inspections Focus: 21 CFR, Part 820 Information, Preventive Action and Strategy 1
2 The Authority behind Inspections The Safe Medical Devices Act of 1990 (the SMDA), enacted on November 28, 1990, amended section 520(f) of the act, providing FDA with the authority to add preproduction design controls to the CGMP regulation. This change in law was based on findings that a significant proportion of device recalls were attributed to faulty design of product. The SMDA also added new section 803 to the act (21 U.S.C. 383) which, among other things, encourages FDA to work with foreign countries toward mutual recognition of CGMP requirements. FDA undertook the revision of the CGMP regulation to add the design controls authorized by the SMDA to the CGMP regulation, as well as because the agency believed that it would be beneficial to the public and the medical device industry for the CGMP regulation to be consistent, to the extent possible, with the requirements for quality systems contained in applicable international standards. FDA published the revised CGMP requirements in the final rule entitled Quality System Regulation in the Federal Register of October 7, 1996 (61 FR 52602). This regulation became effective on June 1, 1997 and remains in effect. QSIT 2
3 Scheduling Inspections of Medical Device Manufacturers Priorities for QS Inspection District Offices will target coverage of manufacturers of Class II and Class III devices, utilizing a risk based methodology. Selection of firms will be focused using the risk based list of possibilities: Pre-Market and Pre-Clearance inspections Manufacturers of Class III devices that have never been inspected. Compliance Follow Up/For Cause Inspections 3
4 Scheduling Inspections of Medical Device Manufacturers Priorities for QS Inspection District Offices will target coverage of manufacturers of Class II and Class III devices, utilizing a risk based methodology. Selection of firms will be focused using the risk based list of possibilities: Manufacturers of high risk devices which can be identified by: Devices with a higher frequency of recalls and MDRs; Devices that are driven by software and those with rapidly evolving technological changes. Both of these types of devices are subject to rapid and potentially poorly controlled modifications that could affect their continued safety and efficacy; or, New devices that have not been manufactured and distributed for very long. Single Use Device re-processors: Hospital re-processors and Third Party re-processors. Highest priority will be given to those Class III device manufacturers that have not been previously inspected. 4
5 Class I Medical Device Manufacturers All Class I devices, including those exempted from most of the Quality System regulation requirements, must comply with record keeping requirements and complaint file requirements, as well as reporting requirements under the MDR regulation. Class I manufacturers should not be routinely scheduled for inspection but should receive lowest inspectional priority unless addressed by a special, For Cause assignment or when a health hazard is apparent. 5
6 Inspectional Strategy The QS inspectional goal is to assess the firm s quality management system for compliance with the appropriate regulations. The QS inspections should generally start with a walk through of the facility to become familiar with the firm s operations and general state of control. 6
7 Inspectional Strategy The inspection will assess the firm s systems, methods, and procedures to ensure that the firm s quality management system is effectively established (defined, documented and implemented) and effectively maintained. QS inspections should include the assessment of postmarket information on distributed. 7
8 Inspectional Strategy Due Diligence QS inspections should include the assessment of post-market information on distributed devices to include: Review of recalls Review of MDRs (Be alert to the fact that MDRs may contain information on recalls that have not been reported through the district) Review of corrections and removals Review of significant changes in device specifications or in the manufacturing specifications Follow-up on previous FDA 483 observation(s), to include the corrections, corrective actions or preventive actions for the observation(s) and the related system(s) 8
9 Inspectional Strategy Available post-market information should be reviewed as a part of the preparation for the inspection, in order to facilitate efficient time spent at the facility. Identify in the EIR post-market information reviewed during the inspection and adequately document your findings. See IOM Any problems identified as a result of the review of post-market information should be developed during the inspection. Important Note : The review of post-market information does not mean that the investigator should open the inspection with the review of complaints and complaint information. Complaints should be reviewed within the context of the Corrective and Preventive Action sub-system according to the procedures described below in this part. 9
10 Inspectional Strategy QS inspections should generally be conducted using the Quality System Inspection Technique (QSIT). Guidance for performing an inspection is provided in the Guide to Inspections of Quality Systems, August 1999, also called the QSIT Guide. This QSIT tool can be scaled to meet the needs of each particular inspection. The table below correlates the level of inspection and the guidance on how to perform the inspections. 10
11 Inspectional Strategy Inspection Level Type of Inspection Guide to Inspections 1 Abbreviated QSIT Two subsystems; Corrective and Preventive Actions (CAPA) plus Production and Process Controls (P&PC) or Design Controls 2 Comprehensive QSIT - The four major subsystems; Management Controls, Design Controls, CAPA and P&PC 3 Compliance Follow-up - As directed by inspectional guidance and Special For Cause - elements of QSIT As directed by inspectional guidance and elements of QSIT 11
12 Inspectional Strategy Compliance Follow-up and For Cause inspections are dictated by the previous FDA 483 findings and other regulatory information and may differ from the typical QSIT approach. The inspectional guidance provided by the assignment, the district compliance branch, and/or CDRH will guide the direction of these inspections. However, elements of the QSIT Guide may also be utilized. Investigators must ensure that the EIR clearly states what was covered during the inspection due to the directed nature of these types of inspections. 12
13 Inspectional Strategy NOTE: The Quality System regulation can be grouped into seven subsystems; however, the following four subsystems are considered major subsystems and are the basic foundation of a firm s quality management system: Management Controls, Design Controls, Corrective and Preventive Actions (CAPA), and Production and Process Controls (P&PC). MDR, Corrections and Removals, and Tracking requirements (where applicable) should be covered when covering the CAPA subsystem. The three remaining subsystems (Facilities and Equipment Controls, Materials Controls and Document/Records/Change Controls) cut across a firm s quality management system and are evaluated while covering the four major subsystems. 13
14 Inspectional Strategy This process for performing subsystem inspections is based on a "topdown" approach to inspecting. The subsystem approach is designed to provide you with the key objectives that can help determine a firm's state of compliance. The process was designed to account for the time constraints placed on field investigators when performing device quality system inspections..focus the effort on key elements of a firm's quality system..efficiently and effectively evaluate that quality system. 14
15 Inspectional Strategy Instruction to Investigators: When you begin an inspection by looking at one or more instances of quality problems, such as nonconforming device reports, and work your way back through the firm's quality system, you are doing a "bottom-up" inspection. This method has been helpful in zeroing in on specific problems, and evaluating the firm's actions relating to those problems. However, with the "top-down" approach, we are looking at the firm's "systems" for addressing quality before we actually look at specific quality problems. In the "top-down" approach, we "touch bottom" in each of the subsystems by sampling records, rather than working our way from records review backwards towards procedures. 15
16 Inspectional Strategy The "top-down" approach begins each subsystem review with an evaluation of whether the firm has addressed the basic requirements in that subsystem by defining and documenting appropriate procedures. This is followed by an analysis of whether the firm has implemented the requirements of that subsystem. 16
17 Inspectional Strategy Record Review One similarity between "top-down" and "bottom-up" inspectional approaches is record review. Both approaches involve review of raw data, or individual records. In the "top-down" approach, however, we are asking you to use a sampling approach to the record review. With the "top-down" approach, you will sample records in many of the subsystems to verify whether or not the firm is in compliance. In other words, you are doing the raw data review as you did in the past, but in a more controlled manner. The FDA provides sampling tables to assist in determining how many records you need to review, and what confidence you can have in the potential prevalence of the observed conditions. 17
18 Level One Inspection This level of inspection (CAPA plus P&PC or Design Controls) may be used for routine surveillance and initial inspections of all firms, other than firms that manufacture Class III devices. However, it is recommended that initial inspections of Class II manufacturers utilize a Level 2 Comprehensive inspection whenever district resources permit. Level 1 inspections should cover the CAPA subsystem, then P&PC or Design Controls, using the QSIT Guide. The selection of CAPA plus either the P&PC or Design Controls subsystem will provide an adequate review of the compliance status of the firm. 18
19 Level One Inspection QSIT Guide. The selection of CAPA plus either the P&PC or Design Controls subsystem will provide an adequate review of the compliance status of the firm. The following should be considered in determining whether to select P&PC or Design Controls: CAPA findings during the inspection; Subsystems covered during the previous EI. The previous EIR(s) should be reviewed to determine which subsystems were previously covered. The selection of the P&PC or Design Controls subsystem should be alternated over time so that more subsystems within a firm s overall quality management system are assessed; Significant changes since the previous EI. Determine if there were any design changes which required a new submission or application, or if there were any major process changes; and, Post market information indicating potential design problems. The EIR must clearly state which subsystem P&PC or Design Controls was chosen and why. Note: The adequacy of the correction(s), corrective action(s) or preventive action(s) related to any FDA 483 item(s) from the previous inspection will be covered, even if the entire subsystem will not be reviewed during the current Level 1 inspection. 19
20 Level Two Inspection Level 2 inspections are Comprehensive Inspections. Level 2 inspections will cover all four major subsystems (Management Controls, Design Controls, CAPA, and P&PC) as explained in the QSIT Guide. The Level 2 inspection is considered a comprehensive review of the compliance status of the firm. Level 2 inspections will be performed: For all initial inspections of Class III device manufacturers and where possible Class II device manufacturers For foreign inspections For training When an inspection, which started out as Level 1, reveals post market information and/or objectionable conditions which cannot be adequately assessed as a Level 1 inspection. 20
21 Level Two Inspection The Level 2 QSIT approach was validated using the following inspectional sequence: Management Controls, Design Controls, CAPA and P&PC. This inspectional sequence allows the investigator to review design control issues and how the device specifications were established before reviewing the CAPA subsystem. Investigators may however start with Management Controls, followed by CAPA, Design Controls, and P&PC with appropriate linkages. Information from Design Controls and CAPA may be used to select the products and processes for inspecting production and process controls, and appropriate linkages. The subsystems may be inspected in any appropriate and justifiable sequence in order to perform a timely and effective inspection. 21
22 Level Two Inspection The Level 2 QSIT : This approach is affected by: Selection of manufacturing processes for inspectional coverage should include the following considerations: CAPA indicators of process problems Processes used to manufacture high risk products Processes that have a high risk of causing product failure Processes that require process validation Processes that are new to the manufacturer Processes that cover a variety of process technologies and profile classes Common processes used in multiple products Processes not covered during previous inspections It is important to thoroughly cover Purchasing Controls, to include outsourced processes, as a QSIT linkage under P&PC whenever P & PC is covered. The Purchasing Control coverage must be documented in the EIR especially if the manufacturer contracts a sterilization process or contracts the manufacture of significant components, subassemblies, or processes. 22
23 Level Two Inspection Manufacturing Focus Selection of manufacturing processes for inspectional coverage should include the following considerations: CAPA indicators of process problems Processes used to manufacture high risk products Processes that have a high risk of causing product failure Processes that require process validation Processes that are new to the manufacturer Processes that cover a variety of process technologies and profile classes Common processes used in multiple products Processes not covered during previous inspections 23
24 Level Two Inspection Purchasing Controls It is important to thoroughly cover Purchasing Controls, to include outsourced processes, as a QSIT linkage under P&PC whenever P & PC is covered. The Purchasing Control coverage must be documented in the EIR especially if the manufacturer contracts a sterilization process or contracts the manufacture of significant components, subassemblies, or processes. 24
25 The chart below describes the steps for the Level 3 domestic inspection after a Level 2 inspection. 25
26 For Cause Inspections For Cause inspections are carried out in response to specific information that raises questions, concerns, or problems associated with a FDA regulated firm or commodity. This information could come to the attention of FDA from any source and including but not limited to, the following: Results of a sample analysis; Observations made during prior inspections; Recall or market withdrawal; Consumer or employee complaint / Whistle Blowing Adverse reaction report; or, Suspicion of fraud. For Cause inspections are usually initiated at the request of CDRH, ORA headquarters, Regional or District directives. For Cause inspections are dictated by the source of information and may differ from the typical QSIT approach. These inspections are generally more in-depth in particular areas than typical QSIT inspections 26
27 Foreign Inspections All foreign inspections should be conducted using the QSIT Guide under the Level 2 strategy, and any special instructions contained in the inspection assignment. The foreign manufacturer's compliance with registration and listing requirements should be covered during foreign inspections. The failure of foreign device manufacturers to list products exported to the US will subject medical devices to detention upon entry. 27
28 483 Statement Part of your Strategy The following statement should be included on each FDA 483: This document lists observations made by the FDA representatives during the inspection of your facility. They are inspectional observations and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective actions in response to an observation, you may discuss the objection or action with FDA representatives during the inspection or submit this information to FDA. For all medical device inspections the FDA 483 should contain the following additional statement: The observations noted in this form FDA 483 are not an exhaustive listing of objectionable conditions. Under the law, your firm is responsible for conducting internal self audits to identify and correct any and all violations of the quality system requirements. 28
29 Preparing for the Inspection 29
30 A Mindset For Everyday Record Keeping Training Document and Data Controls Internal Quality Auditing CAPA The Quality Policy Process Linkages Non-Conforming Product Complaints Management Responsibility Design Linkages with the QRB Manufacturing Batch Records 30
31 FDA Inspection Procedure Arrival of the Inspector The Inspection Team The Inspection Coordinator Focus The Control Room Photograph Policy Record Keeping Responsibilities Contact Information Document, Information and Sample Requirements 31
32 Other Sites as well Liaison Inspection Room Notes person Spokes person FDA Output Runner Input Hot Line Control Room Hot Line Info Trail output 32
33 The Control Room Logistics / Materials In close proximity to the FDA inspection room...but not too close Two or three telephones, two faxes, and active address Flip charts and magic markers Controlled copies of procedures A fast copy machine File folder units for categorizing documents and records Plenty of clerical supplies Sticky notes A hot line between the FDA Inspection Room & Control Room 33
34 The Control Room Team Qualified personnel with a strong systems background - cgmp-qsr savvy - Very familiar with the paperwork flow - Know where the gaps might be - Been through FDA inspections in the past.. street smart - Not necessarily management (preferably not) - Linkages savvy - Quick thinkers with inquiring minds - Endurance (long pauses and quick starts) - Know the right people and what buttons to push - Free thinkers..creative - Without boundaries 34
35 Having an experienced auditor in the room is a plus.. Anticipate the next steps..i.e. as you would audit the next steps..your audit checklist! 35
36 GOAL: To get the information to the inspection room as quickly as possible, but no longer than ONE Day 36
37 Investigators are not entitled to review the following information: Management Review Minutes Internal Audit Results Supplier Audit Results 37
38 Process Flow thinking this way Responsibility Responsibility Task or Activity SOP Record Task or Activity SOP 38
39 Think Inputs / Outputs INPUT TASK OR ACTIVITY OUTPUT 39
40 Think Five Moves in Advance TASK OR ACTIVITY TASK OR ACTIVITY 1 TASK OR ACTIVITY 2 Etc. TASK OR ACTIVITY 3 TASK OR ACTIVITY TASK OR ACTIVITY
41 The Control Room you re only as good as your info Complaint Files Archives Document Control Operations Regulatory Affairs Control Room Dedicated Phone Line FDA Inspection Room 41
42 The Control Room presentation is one key facet Control Room Inspection Ready FDA Inspection Room 42
43 Scenarios based upon - process orientation - process logic - process anticipation 43
44 Inspector asks for Objective Evidence Inside Liaison calls the Control Room Hot Line Control Room Plots out the Scenario Start Thinking Linkages Control Room asks for Level One Information Information Arrives in the Control Room Control Room Audits the Information Tags as Needed Asks for More? Info-Aware Objective Evidence 44
45 ..if there is a specific product involved have the following ready before hand: 510(k) Letters to File PMA FMEA DHF DMR DHRs Validation Master Plan CAPA Log Calibration Master Plan etc. 45
46 ..if there is a specific batch involved have the following ready before hand: Batch Record(s) DHF DMR DHR Put together a batch time-line with dates, tasks, records, people, etc. be prepared Certificates Sterility Data Training Records Non-conforming Product etc. 46
47 Common Linkages..to anticipate the next steps Organizational Structure Job Descriptions Responsibility and Authority Training Records 47
48 30,000-foot process map in control room (a reference..point of order..a reminder) Supplier ships raw material Incoming receipt and testing Warehouse controls Release to Production Production & Process Controls Product and Process Disposition Release to be shipped Customer Receipt 48
49 A Simple Scenario..to anticipate the next steps Design History File The Wall Device Master Record e.g. Design Transfer.. Essential Outputs DMR Design Verification Acceptance Activities Packaging and Labeling Label Claims Purchasing Controls Approved Supplier List 49
50 A Simple Scenario..to anticipate the next steps Product Non-conformances Management Review Audit Findings Reporting C/A Trends Complaints and MDRs P/A 50
51 Scenarios from Warning Letters Failure to establish and maintain adequate procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR (i). For example, your design control procedures did not include a procedure to ensure that design changes of existing products would include verification or where appropriate validation. 51
52 Scenarios from Warning Letters Failure to establish adequate procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR For example not all areas of the quality system are being audited as prescribed by SOP Specifically. customer interfaces (including the complaint handling system) have not been audited since Control of nonconforming product and the CAPA system have not been audited since May
53 Scenarios from Warning Letters You have failed to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR (i). Specifically, a change was implemented for the design of the hub on the aspirating dental injection syringe because the hubs were falling off and the needles would not stay on. However, there is no data or documentation supporting the verification, review, and approval of design change. 53
54 Scenarios from Warning Letters You have failed to establish and maintain adequate procedures to ensure that device history records for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record, as required by 21 CFR Specifically, the firm's device history record for the aspirating dental injection syringes is the Job Traveler implemented in However, only 3 travelers exist for all syringe products manufactured and shipped from 12/ /
55 Scenarios from Warning Letters You have failed to appoint and document such appointment of a member of management who, irrespective of other responsibilities, ensures that quality system requirements are effectively established and effectively maintained and reports on the performance of the quality system to management with executive responsibility, as required by 21 CFR (b)(3). Specifically, during the inspection, you stated that the firm had not appointed a management representative to the firm's quality system, to ensure the quality system requirements were met. Specifically, the firm does not have procedures for management review and management has not reviewed the suitability and effectiveness of the quality system at defined intervals and with sufficient frequency. 55
56 Scenarios from Warning Letters Failure to provide adequate resources including the assignment of trained personnel, for management, performance of work, and assessment activities, including internal quality audits, as required by 21 CFR (b)(2). Specifically, the current inspection demonstrated that there is no documentation to show that personnel performing the assembly and inspection of the aspirating dental injection syringe were trained. In addition, there are no personnel trained to conduct internal quality audits. We have reviewed your responses and have concluded that they are inadequate. Your firm promised to correct the deficiencies without providing evidence of implementation of the correction, corrective action and proposed preventive action. 56
57 Scenarios from Warning Letters The documentation provided by the establishment inspection showed that your firm did not perform an evaluation of the magnitude of a component problem that resulted in a recall to see if it was endemic to other device models. Your firm had identified and verified the root cause and had implemented a correction by January 19, 2009, but as of February 27, 2009, your firm was unable to detail the impact of the problem on other devices to the investigators on site. The firm s CAPA procedure indicates that; an evaluation of the magnitude of the issue once the investigation of root cause is completed, should be performed. 57
58 Scenarios from Warning Letters Failure to maintain a Device Master Record as required by 21 CFR For example, you did not have a Device Master Record which included, or referred to the location of, device specifications or procedures for production and quality assurance. Failure to maintain Device History Records, which is a requirement of 21 CFR For example, you did not maintain records of device assembly or acceptance testing. Failure to establish procedures for finished device acceptance as required by 21 CFR (d). For example, you did not have written procedures for finished device testing including instructions for how to document testing. Failure to establish procedures for acceptance of incoming product, which is required by 21 CFR (b). For example, you did not have written procedures for incoming inspection including instructions for how to document testing. Failure to establish adequate procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR (a). For example, your Procedure No , Customer Complaint and Returns, was in draft form and had not been implemented. 58
59 Scenarios from Warning Letters Failure to review and evaluate complaints to determine whether an investigation is necessary, which is required by 21 CFR (b). For example, complaints (leaking), (problem with sterilizer), and (defective), were not reviewed, evaluated, and investigated. 59
60 Scenarios from Warning Letters Failure to establish adequate procedures to control product that does not conform to specified requirements, which is required by 21 CFR (a). For example, your Procedure No , Non Conforming Material, had not been fully implemented, and a Nonconforming Material Report was in draft form 60
61 Scenarios from Warning Letters You do not have an agreement that requires your solenoid valve supplier to provide notification of changes to specification. According to CAPA 002, you determined that XXXXX provided solenoid valves that were model number instead of after you found that the valves were noisy. You do not have an agreement with XXXXX that requires that XXXXX notify you of changes to the supplied product. Failure to include an agreement in purchasing documents that the suppliers, contractors, and consultants agree to notify the manufacturer of changes in the product or service so that manufacturers may determine whether the changes may affect the quality of a finished device, as required by 21 CFR (b) 61
62 Scenarios from Warning Letters Failure to establish and maintain procedures for implementing corrective and preventive action (CAPA), as required by 21 CFR (a). For example, your firm has not established or implemented written procedures for implementing CAPA. The only management official on site explained he was not aware of the requirements. We reviewed your response and conclude it is inadequate because the CAPA section of the XXXXX Policy and Procedures Manual", dated September 10, 2010, fails to provide the steps for verifying or validating the CAPA to ensure such action is effective and does not adversely affect the finished device. Additionally, there is no approval signature for this document. 62
63 Scenarios from Warning Letters We reviewed the "Control of Non-Conforming Material" section of the XXXXX Policy and Procedures Manual, included in your response, and note it fails to require an evaluation of the nonconformance including a determination of the need for an investigation and notification to the persons or organizations responsible for the nonconformance. Additionally, there is no evidence the XXXXX Policy and Procedures Manual, has been reviewed, approved and implemented. 63
64 Scenarios from Warning Letters We reviewed your response and conclude it is inadequate because your complaint handling procedure has not been revised to comply with the regulation requirements. Specifically, you included a copy of XXXXX, "Product Complaint Form" with your response. This form includes a space for selecting yes or no as an answer to the question of the need to generate an MDR as a result of the complaint. However, the form does not provide for documenting the evaluation of the need for MDR reporting and justification of the decision. No evidence was provided to demonstrate the corresponding "Complaint Handling" procedure was modified to include the instructions to evaluate and document the need to report the complaint as an event under 21 CFR
65 Scenarios from Warning Letters Failure to document acceptance activities, as required by 21 CFR (e). For example your firm failed to document all of the acceptance activities which are performed such as inspections, tests, and other verification activities. We reviewed your response and conclude it is inadequate because there is no evidence to demonstrate the inspections, tests and other verification activities are being documented. 65
66 Scenarios from Warning Letters You included a copy of the Section , "Device History Record", with your response. This document indicates the computerized system YYYYY is used to maintain device history records. No evidence was provided to demonstrate such system has been validated and implemented. No evidence was provided to demonstrate procedures to document acceptance activities using the computerized system have been developed and implemented. 66
67 Scenarios from Warning Letters Failure to establish and maintain procedures to ensure all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR For example, your firm failed to establish purchasing control procedures and to define and implement adequate quality controls which must be met by suppliers and contractors. The only management official on site explained he was not aware of the written purchasing control procedures were required. We reviewed your response and concluded it is inadequate because no evidence was provided to demonstrate procedures have been established to ensure all purchased or otherwise received product and services conform to specified requirements. You included a copy of a certificate of conformance for one material vendor; however, a copy of an approved purchasing control procedure was not provided. 67
68 Scenarios from Warning Letters Failure of management with executive responsibility to review the suitability of the quality system at defined intervals and with sufficient frequency according to established procedures to ensure the quality system satisfies the requirements of this part, as required by 21 CFR (c). For example, your firm failed to establish and implement written management review procedures. The only management official on site explained he was not aware of the requirements. 68
69 Scenarios from Warning Letters Failure to report to the FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information. from any source. that reasonably suggests that your marketed device malfunctioned and that this device or a similar device, marketed, would be likely to cause or contribute to a death or serious injury if the malfunction were to reoccur as required by 21 CFR (a)(2). 69
70 Scenarios from Warning Letters Failures to develop, maintain, and implement a written MDR procedure, as required by 21 C.F.R For example: Section 5-9 of your MDR procedure, document no. XXXXX, defines the term "becomes aware." This definition, however, is not consistent with the language in 21 C.F.R Your MDR procedure lacks clarity about the roles and responsibilities for your MDR reporting decision-making and record-keeping, See 21 C.F.R Your MDR procedure does not adequately address who makes the final determination of whether an event must be reported as an MDR to FDA and when or how MDR events are detected. Your MDR procedure lacks information about the requirements for establishing and maintaining MDR files or records. See 21 C.F.R
71 Scenarios from Warning Letters You introduced the XXXXX single use applicator in You used the same testing criteria that had been established for the reusable applicator. You determined that there were differences in the properties of the single use and re-usable applicators, this resulted in the issuance of CAPA in The CAPA identified the plastic sheath thickness as a contributor to process variability but no corrective action was initiated for this potential root cause identified. You continue to have nonconformance rejects for not meeting the test criteria. The device history showed that 11 of the batches reviewed included some non-conformances. Data analysis for these non-conformances has not been performed and there has been no additional evaluation as to whether this data should initiate a new CAPA to address the existing nonconformances. A review of the statistical process control sheets for the test for three of the batches showed that the process is not operating in a state of control. The control charts for Lot showed that the process regularly exceeded the control limits and the limit is not met at times. Data analysis for these non-conformances has not been performed and there has been no additional evaluation as to whether this data should initiate a new CAPA to address the existing non-conformances. 71
72 Scenarios from Warning Letters Failure to establish and maintain adequate procedures for verifying the device design outputs meets the design input requirements, as required by 21 CFR (f). For example, the Device History File (DHF) for the surface applicator study for the XXXXX product did not include documentation that acceptance criteria were established. We have reviewed your response dated July 23, 2010, and have concluded that is inadequate because you promised to re-examine the concerns related to the device history file for the surface applicator and forward the results to the FDA. However, you have not yet forwarded the results to the FDA. 72
73 Scenarios from Warning Letters Failure to establish and maintain adequate procedures for validating the device design to ensure that devices conform to defined user needs and intended uses to include risk analysis, where appropriate, as required by 21 CFR (g). For example, the design plan for the Surface Applicator indicates that validation was completed on June 13, 2010; however, there was no documentation that the pre-determined user needs and intended uses were validated. A review of the risk analysis report and assessment stated that the hazard of thermal penetration beyond the target tissue would be mitigated by user training. There was no evidence of validation of the design for user needs and intended uses and no evidence that this risk was indeed mitigated. We have reviewed your response dated July 23, 2009, and have concluded that it is inadequate because you promised to develop a protocol and conduct a clinical evaluation of the Applicator (Attachment 5-User Needs Document in order to validate the design. You promised to forward the final report to the FDA upon completion and did not. 73
74 Final Words Be Prepared! Get Organized! Set the Tone! John Gagliardi 74
ORACLE CONSULTING GROUP
ORACLE CONSULTING GROUP 9 Golder Ranch Rd., Ste. 1 Tucson, Arizona 9 Web Site: E-mail: 20-2-0 20-2-0 (FAX) CONSULTING MEMORANDUM QUALITY SYSTEM INSPECTION TECHNIQUE
More informationCorrective and Preventive Action Background & Examples Presented by:
Corrective and Preventive Action Background & Examples Presented by: Kimberly Lewandowski-Walker Food and Drug Administration Division of Domestic Field Investigations Office of Regulatory Affairs Overview
More informationORACLE CONSULTING GROUP
ORACLE CONSULTING GROUP An Official United States Agent Firm for Foreign Establishments CONSULTING MEMORANDUM: DEALING WITH A MEDICAL DEVICE IN THE U.S. 5398 Golder Ranch Rd., Ste. 1 Tucson, Arizona 85739
More informationHow to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters
environmental failure analysis & prevention health technology development How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters Kevin L. Ong, Ph.D., P.E. Managing
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 7 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2014 Inspections, Compliance, Enforcement, and Criminal Investigations
More information2014 Annual FDA Medical Device Quality System Data. FDA Form 483 Observations and Warning Letter Citations
2014 Annual FDA Medical Device Quality System Data FDA Form 483 Observations and Warning Letter Citations Why is FDA making these data available? In support of the FDA s Transparency and Case for Quality
More informationGxP Process Management Software. White Paper: Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations
GxP Process Management Software : Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations Most FDA violations involve one of the following: Not having procedures in a regulated area
More informationPROGRAM 7382.845. Field Reporting Requirements
PROGRAM 7382.845 SUBJECT: INSPECTION OF MEDICAL DEVICE MANUFACTURERS IMPLEMENTATION DATE October 1, 2000 COMPLETION DATE September 30, 2004 DATA REPORTING PRODUCT CODES PRODUCT/ASSIGNMENT CODES 73-91 82845A
More informationIVD Regulation Overview. Requirements to Assure Quality & Effectiveness
IVD Regulation Overview Requirements to Assure Quality & Effectiveness CLIAC Jan. 2002 Statutory and Regulatory Requirements Statute: Food, Drug, and Cosmetic Act Food and Drugs Act of 1906 Food and Drug
More informationQUALITY MANUAL ISO 9001. Quality Management System
Page 1 of 20 QUALITY MANUAL ISO 9001 Quality Management System Printed copies are not controlled unless marked "CONTROLLED". Upon receipt of this document, discard all previous copies. Page 2 of 20 Approval
More informationOverview of Medical Device Design Controls in the US. By Nandini Murthy, MS, RAC
Overview of Medical Device Controls in the US By Nandini Murthy, MS, RAC 18 controls are a regulatory requirement for medical devices. In the US, compliance with the design controls section of 21 Code
More informationUNCONTROLLED COPY FOR REFERENCE ONLY
CLOVER MACHINE AND MFG. 800 MATHEW ST. #101 SANTA CLARA, CA 95050 727-3380 727-7015 fax REVISION: DATE: PAGE 1 OF 45 QUALITY POLICY MANUAL DISTRIBUTION LIST: President Purchasing Manager Vice President
More informationTable of Contents. Preface 1.0 Introduction 2.0 Scope 3.0 Purpose 4.0 Rationale 5.0 References 6.0 Definitions
Table of Contents Preface 1.0 Introduction 2.0 Scope 3.0 Purpose 4.0 Rationale 5.0 References 6.0 Definitions 7.0 Objectives and User Needs of a Regulatory Audit Report 7.1 Audit report objectives 7.2
More informationSUPPLIER QUALITY MANAGEMENT SYSTEM QUESTIONNAIRE
Company Name Street Address City, State, Zip code Phone Number Fax Company Website Email Address ORGANIZATION NAME PHONE NUMBER EMAIL ADDRESS President/CEO General Manager Engineering Manager Production
More informationQuality Management System Manual
Effective Date: 03/08/2011 Page: 1 of 17 Quality Management System Manual Thomas C. West Eric Weagle Stephen Oliver President ISO Management General Manager Representative Effective Date: 03/08/2011 Page:
More informationINTEGRATED MANAGEMENT SYSTEM MANUAL IMS. Based on ISO 9001:2008 and ISO 14001:2004 Standards
INTEGRATED MANAGEMENT SYSTEM MANUAL IMS Based on ISO 9001:2008 and ISO 14001:2004 Standards Approved by Robert Melani Issue Date 30 December 2009 Issued To Management Representative Controlled Y N Copy
More informationRow Manufacturing Inc. Quality Manual ISO 9001:2008
Row Manufacturing Inc. Quality Manual ISO 9001:2008 Row Manufacturing 210 Durham Drive Athens, Alabama 35611 Phone:256.232.4151 Fax:256.232.4133 Page 2 of 33 This Page intentionally left Blank Page 3 of
More informationAS9100 Quality Manual
Origination Date: August 14, 2009 Document Identifier: Quality Manual Revision Date: 8/5/2015 Revision Level: Q AS 9100 UNCONTROLLED IF PRINTED Page 1 of 17 1 Scope Advanced Companies (Advanced) has established
More informationMicro Plastics, Inc. Quality Manual
ISO 9001:2008 11 Industry Lane Flippin, Arkansas 72634 QM-001-2008-F Page 2 of 39 Introduction Micro Plastics, Inc. developed and implemented a Quality Management System in order to document the company
More informationSection 5: Quality Systems Regulation (QSR) and Good Manufacturing Practice (GMP)
Section 5: Quality Systems Regulation (QSR) and Good Manufacturing Practice (GMP) 1 Quality Systems Regulation (QSR) 2 Quality Systems Regulation (QSR) and Good Manufacturing Practice (GMP) Sets of checks
More informationQuality Management System Manual ISO9001:2008
Quality Management System Manual ISO9001:2008 Controlled Copy Rev. 3 Page 1 of 21 7/1/13 Table of Contents Company Profile...5 Past...5 Present...5 Mission...5 Vision...5 Locations...6 1 Scope...6 1.1
More informationISO 9001:2000 AUDIT CHECKLIST
ISO 9001:2000 AUDIT CHECKLIST No. Question Proc. Ref. Comments 4 Quality Management System 4.1 General Requirements 1 Has the organization established, documented, implemented and maintained a quality
More informationQUALITY MANUAL REVISION RECORD
Page 2 of 31 REVISION RECORD Date Rev Description Jun 18, 2007 N/C Original Issue Sep 16, 2009 A Update to ISO 9001:2008 Standard. Feb 04, 2010 B Revised exclusions, removed (Except 7.3.7 from the exclusion
More informationCompany Quality Manual Document No. QM Rev 0. 0 John Rickey Initial Release. Controlled Copy Stamp. authorized signature
Far West Technology, Inc. ISO 9001 Quality Manual Document No.: QM Revision: 0 Issue Date: 27 August 1997 Approval Signatures President/CEO Executive Vice President Vice President/CFO Change Record Rev
More informationSpecialties Manufacturing. Talladega Castings & Machine Co., Inc. ISO 9001:2008. Quality Manual
Specialties Manufacturing Talladega Castings & Machine Co., Inc. ISO 9001:2008 This document is the property of TMS and may not be reproduced, wholly, or in part, without the express consent of TMS. Rev.
More informationQuality Management Systems Manual
Washington Division Quality Management Systems Manual ISO 13485:2003 DOCUMENT NUMBER 01-QM-MED REVISION LEVEL 01 PAGE 1 of 40 This manual describes the quality management systems structure at GM Nameplate
More informationISO 9001 Quality Systems Manual
ISO 9001 Quality Systems Manual Revision: D Issue Date: March 10, 2004 Introduction Micro Memory Bank, Inc. developed and implemented a Quality Management System in order to document the company s best
More informationQuality Management System Manual
Quality Management System Manual Assurance ISO / AS Manual Quality Management System EXCEEDING ALL EXPECTATIONS Since our inception in 1965, Swiss-Tech has supplied the medical, aerospace, hydraulic, electronic
More informationDesign Verification The Case for Verification, Not Validation
Overview: The FDA requires medical device companies to verify that all the design outputs meet the design inputs. The FDA also requires that the final medical device must be validated to the user needs.
More informationCAPA - the importance of data analysis
CAPA - the importance of data analysis Presented by: Sue Jacobs QMS Consulting, Inc. 1 847 359 4456 sue@qmsconsultant.com QMS Consulting, Inc. 2007 1 Topics Regulatory Requirements Design Controls and
More informationComparison between FDA QSR and ISO 13485
Comparison between FDA QSR and ISO 13485 Most countries in the world including the Europe, for the conformity assessment of medical devices to be used by their countrymen, assess not only whether the product
More informationInternal Audit Checklist
Internal Audit Checklist 4.2 Policy Verify required elements Verify management commitment Verify available to the public Verify implementation by tracing links back to policy statement Check review/revisions
More informationQuality Management System Manual Revision L
This Page 1 of 35 of the Quality Management System Manual If issued as a controlled copy, the serial number of this copy is Quality Management System Manual Certified to AS9100 Revision C Printed copies
More informationDNV GL Assessment Checklist ISO 9001:2015
DNV GL Assessment Checklist ISO 9001:2015 Rev 0 - December 2015 4 Context of the Organization No. Question Proc. Ref. Comments 4.1 Understanding the Organization and its context 1 Has the organization
More informationRevision Date Author Description of change. 10 07Jun13 Mark Benton Removed Admin. Manager from approval
Page 2 of 15 Document Revision History Revision Date Author Description of change 10 07Jun13 Mark Benton Removed Admin. Manager from approval 12Feb13 Mark Benton 08 01Oct12 Mark Benton 07 8/30/2012 Refer
More informationCombination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma
Combination Products Presented by: Karen S. Ginsbury For: IFF March 2014 Types of products Biological and medical device (freeze dried + syringe dual volume) Medical device and plasma devised product (syringe)
More informationCartel Electronics. AS 9100 Quality Systems Manual
Cartel Electronics AS 9100 Quality Systems Manual 1900 C Petra Lane Placentia, California 92870 Introduction Cartel Electronics, as a global supplier to the aviation, space, and space industries, has developed
More informationCorrespondence between ISO 13485:2003 and the US Quality System Regulation
Correspondence between ISO 13485:2003 and the US Quality System Regulation Correspondence between ISO 13485:2003 and the US Quality System Regulation 1 Scope 1.1 General This International Standard specifies
More informationSurgi Manufacturing Quality Manual
Surgi Manufacturing Page 1 of 18 Approvals: QA: Eng. Mgt. : A Date: 18Aug98 1. Introduction... 4 1.1 Scope... 4 1.2 Purpose... 4 1.3 Authority... 4 1.4 Issue of the Manual... 4 1.5 Amendments... 4 1.6
More informationISO 13485:201x What is in the new standard?
ISO 13485:201x What is in the new standard? Eric Finegan, Quality Mgr, BTE Technologies, Inc. 2015-09-10 1 Presentation Slides This slide deck is the presentation performed on 2015-09-10. A more detailed
More informationCOMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS
COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance
More informationQuality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702
Quality Management System MANUAL SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Doc. No. G5500 Rev. 9.1 Status : APPROVED Effective: 12/11/2014 Page 2 of 23 Quality Manual Table of Contents
More informationCorrective and Preventive Actions
Corrective and Preventive Actions A Five Step Approach Topics to Be Covered What is CAPA? Governing authority Five steps to a good CAPA process Where companies have difficulty Example citations Recap What
More informationMaking SOP Training More Effective
By David Peterson, Director, GMP and Quality Systems, UL EduNeering SOPs are critical to efficient operations, quality control and regulatory compliance. This paper reviews best practices for the Life
More informationQUALITY MANAGEMENT SYSTEM (QMS) ASSESSMENT CHECKLIST
1. QUALITY MANAGEMENT SYSTEM QUALITY MANAGEMENT SYSTEM (QMS) ASSESSMENT CHECKLIST 1.1 Quality Management System General 1.1.1 Is objective evidence available to demonstrate that the MDSAP site has defined,
More informationPreparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant
Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives Barry A. Friedman, Ph.D. Consultant FDA Overview FDA is a consumer protection agency within the Department of Health & Human
More informationProcess Validation for Medical Devices
Process Validation for Medical Devices Dan O Leary CBA, CQE, CRE, CSSBB, CIRM, LLC 603-209-0600 OmbuEnterprises@msn.com Copyright 2010 by, LLC Process Validation for Medical Devices 1 Instructor Introduction
More informationCHAPTER 7 - RECALL ACTIVITIES
CHAPTER 7 INVESTIGATIONS OPERATIONS MANUAL 2015 CONTENTS CHAPTER 7 - RECALL ACTIVITIES 7.1.1.1 - Recall SUBCHAPTER 7.1 - RECALLS... 368 7.1.1 - DEFINITIONS... 368 7.1.1.1 - Recall... 368 7.1.1.2 - Recall
More informationISO 9001:2000 Gap Analysis Checklist
ISO 9001:2000 Gap Analysis Checklist Type: Assessor: ISO 9001 REQUIREMENTS STATUS ACTION/COMMENTS 4 Quality Management System 4.1 General Requirements Processes needed for the quality management system
More informationFINE LOGISTICS. Quality Manual. Document No.: 20008. Revision: A
FINE LOGISTICS Quality Manual Document No.: 20008 Revision: A 20008 Rev. A FINE LOGISTICS, Quality Manual Page 1 of 24 Quality Manual: Table of contents Number Section Page 1. GENERAL 3 1.1 Index and revision
More informationSchweppes Australia Head Office Level 5, 111 Cecil Street South Melbourne Victoria 3205. www.schweppesaustralia.com.au
Schweppes Australia Head Office Level 5, 111 Cecil Street South Melbourne Victoria 3205 www.schweppesaustralia.com.au Quality Management Systems 1. Quality Management Systems develop, implement, verify
More informationDocuments, Records and Change Control
Documents, Records and Change Control Lori S. Lawless Medical Device Specialist Food and Drug Administration Baltimore District Office Lori.Lawless@fda.hhs.gov (410) 779-5442 May 13-14, 2008 Baltimore
More informationSetting Up A Complaint Handling System. Presented by Sue Jacobs Principal Consultant, QMS Consulting, Inc. Complaint Systems
Setting Up A Complaint Handling System Presented by Sue Jacobs Principal Consultant, QMS Consulting, Inc. January 2008 ~ Orlando, Florida QMS Consulting, Inc. 2008 1 Complaint Systems Written Procedures
More informationCase Study: A Mock-QSIT Audit of Ford & Firestone By Tim Wells
Case Study: A Mock-QSIT Audit of Ford & Firestone By Tim Wells Published in ASQ Biomedical Feedback, Volume 30, No. 1, Winter 2001 Background In December the Firestone Company released a report on the
More informationQuality Management System General
Audit Date: Quality Management System General Requirement: 4.1 and 4.2.2-QMS General Verify Scope Comments/Evidence/Findings: Verify the Exclusions is applicable and justified How are the processes in
More informationISO 9001 (2000) QUALITY MANAGEMENT SYSTEM ASSESSMENT REPORT SUPPLIER/ SUBCONTRACTOR
Page 1 of 20 ISO 9001 (2000) QUALITY MANAGEMENT SYSTEM ASSESSMENT REPORT SUPPLIER/ SUBCONTRACTOR SUPPLIER/ SUBCONTRACTOR NAME: ADDRESS: CITY AND STATE: ZIP CODE: SUPPLIER/MANUFACTURER NO PHONE: DIVISION:
More informationCamar Aircraft Products Co. QUALITY MANUAL Revision D
QUALITY MANUAL Revision D Gujll'y Manual Introduction The purpose of this manual is to describe the Quality Assurance Program implemented by Camar Aircraft Products Co. (hereafter referred to as C.A.P.C.)
More informationKaras Engineering AS9100 QUALITY MANAGEMENT SYSTEM MANUAL
Karas Engineering AS9100 QUALITY MANAGEMENT SYSTEM MANUAL Revision D October 27, 2015 Statement of Commitment and Authority Commitment This Quality Management System Manual (QMSM) delineates the processes,
More informationCompliance Focused Preapproval Preparation Program. By Mike Ronningen, RAC
Compliance Focused Preapproval Preparation Program By Mike Ronningen, RAC 14 July 2011 Submitting a Premarket Approval Application (PMA) for a Class III medical device to the US Food and Drug Administration
More informationInternal Quality Management System Audit Checklist (ISO9001:2015) Q# ISO 9001:2015 Clause Audit Question Audit Evidence 4 Context of the Organization
Internal Quality Management System Audit Checklist (ISO9001:2015) Q# ISO 9001:2015 Clause Audit Question Audit Evidence 4 Context of the Organization 4.1 Understanding the organization and its context
More informationQUALITY MANAGEMENT SYSTEM Corporate
Page 1 of 12 4 Quality Management System 4.1 General Requirements The Peerless Pump Quality Management System shall include: Documented statements of a quality policy and of quality objectives; A quality
More informationSupplier Quality Requirements and Clauses
Supplier Quality Requirements and Clauses Supplier Quality Requirements General The following Quality Notes (QN01 through QN19) apply to and form a part of all Purchase Orders issued by Advanced Conversion
More informationMaking Recall Determinations
Making Recall Determinations AdvaMed January 23, 2008 Orlando, FL Edward C. Wilson, Jr., Esq. Partner Hogan & Hartson LLP (202) 637-5839 ecwilson@hhlaw.com www.hhlaw.com Michael S. Heyl, Esq. Associate
More informationMapping Your Success Top Non-Conformities Requiring a CAPA Process
Mapping Your Success Top Non-Conformities Requiring a CAPA Process Agenda FDA Statistics for 2012 BSI Statistics for 2012 EQMS industry benchmark data About CAPA Traits of Software Solution for CAPA 2
More informationThe President of Inductors Inc. is the senior executive responsible for operations.
Title: Quality Management System Manual Page: 1 of 20 INTRODUCTION Inductors Inc., founded in 1991, specializes in the distribution of inductive components, including but not limited to standard and custom
More informationQuality Manual TABLE OF CONTENTS APPROVAL SIGNATURE PAGE 1.1 1 AMENDMENT RECORD 1.2 2 SCOPE 2.0 3 EXCLUSIONS 2.1 3
TABLE OF CONTENTS DESCRIPTION SECTION PAGE INTRODUCTION 1.0 1 APPROVAL SIGNATURE PAGE 1.1 1 AMENDMENT RECORD 1.2 2 SCOPE 2.0 3 EXCLUSIONS 2.1 3 CORPORATE POLICY 3.0 3 QUALITY MANAGEMENT SYSTEM 4.0 4 GENERAL
More informationConducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc.
Conducting a Gap Analysis on your Change Control System Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc. Standards, Regulations, Guidelines related to Change Control Management
More informationQUALITY OPERATING PROCEDURE QOP-00-02 QUALITY ASSURANCE SYSTEM MANUAL
PAGE 1 OF 40 QUALITY Note: The revision level of this document and any referenced documents must be verified for latest issue before use QOP-00-02 TITLE QUALITY ASSURANCE SYSTEM MANUAL APPROVALS DATE REVISIONS
More informationQuality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702
Quality Management System MANUAL SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Doc. No. G5500 Rev. 9.2 Status : APPROVED Effective: 9/25/2015 Page 2 of 23 Quality Manual Table of Contents
More informationCombining ISO 9001 and ISO 14001 compliance efforts can reduce costs and improve quality
Standard Synergy Combining ISO 9001 and ISO 14001 compliance efforts can reduce costs and improve quality By Christian Lupo, Business Unit Manager Automotive & Aerospace, NSF-ISR, Ann Arbor, MI Many companies
More informationCENTRIS CONSULTING. Quality Control Manual
CENTRIS CONSULTING Quality Control Manual ISO 9001:2008 Introduction Centris Consulting developed and implemented a Quality Management System in order to document the company s best business practices,
More informationISO 9001:2008 STANDARD OPERATING PROCEDURES MANUAL
8200 Brownleigh Drive Raleigh, NC 27617-7423 Phone: (919) 510-9696 Fax: (919) 510-9668 ISO 9001:2008 STANDARD OPERATING PROCEDURES MANUAL ALLIANCE OF PROFESSIONALS & CONSULTANTS, INC. - 1 - Table of Contents
More informationThe following paragraphs, identified to coincide with the OHSAS 18001:2007 numbering system, provide a clause-by-clause summary of the standard.
Summary of OHSAS 18001:2007 Requirements With this article, the 18000 store provides a brief and clear summary of the OHSAS 18001:2007 requirements. First of all, OHSAS 18001 is an international standard
More informationControl No: QQM-02 Title: Quality Management Systems Manual Revision 10 07/08/2010 ISO 9001:2008 Page: 1 of 22
ISO 9001:2008 Page: 1 of 22 Central Technologies has developed a Quality Management System, and the associated procedures and work instructions, to be compliant to ISO 9001:2008. Utilizing this Quality
More informationQUALITY MANUAL ISO 9001:2015
Page 1 of 22 QUALITY MANUAL ISO 9001:2015 Quality Management System Page 1 of 22 Page 2 of 22 Sean Duclos Owner Revision History Date Change Notice Change Description 11/02/2015 1001 Original Release to
More informationMedical Device Reporting (MDR) Requirements the New FDA Draft Guidance
Medical Device Reporting (MDR) Requirements the New FDA Draft Guidance February 27, 2014 Jeffrey K. Shapiro (202) 737-9633 jshapiro@hpm.com 1 Essential Requirements n Submit MDR reportable events to FDA
More informationISO/TS 16949:2002 Guidance Document
ISO/TS 16949:2002 Guidance Document Introduction ISO/TS 16949:2009 emphasizes the development of a process oriented quality management system that provides for continual improvement, defect prevention,
More informationICH Q10 - Pharmaceutical Quality System
WCC PDA Dinner Meeting Jan 2012 ICH Q10 - Pharmaceutical Quality System Neil Wilkinson NSF-DBA www.nsf-dba.com ICHQ10.1 WCC PDA Dinner Meeting Jan 2012 Your Presenter Partner at NSF-DBA USA Training, Consultancy,
More information14620 Henry Road Houston, Texas 77060 PH: 281-447-3980 FX: 281-447-3988. WEB: www.texasinternational.com QUALITY MANUAL
14620 Henry Road Houston, Texas 77060 PH: 281-447-3980 FX: 281-447-3988 WEB: www.texasinternational.com QUALITY MANUAL ISO 9001:2008 API Spec Q1, 9th Edition API Spec 8C 5 Th Edition MANUAL NUMBER: Electronic
More informationThe purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers.
Supplier Quality Standard 1.0 Purpose The purpose of this Supplier Quality Standard is to communicate the expectations and requirements of Baxter Healthcare Corporation to its suppliers. These expectations
More informationQSIT Management Controls. QSIT Workshops
QSIT Management Controls QSIT Workshops Management Controls Importance Assessment Demonstration of Compliance Quality System Design Controls Material Controls Corrective & Preventive Actions Management
More informationFINAL DOCUMENT. Guidelines for Regulatory Auditing of Quality Management Systems of Medical Device Manufacturers Part 1: General Requirements
GHTF/SG4/N28R4:2008 FINAL DOCUMENT Title: Guidelines for Regulatory Auditing of Quality Management Systems of Medical Device Manufacturers Authoring Group: GHTF Study Group 4 Endorsed by: The Global Harmonization
More informationThe Four Elements of an Effective Food Safety Management System
The Four Elements of an Effective Food Safety Management System Plex Online White Paper At a Glance As processors develop and enhance their Food Safety Management Systems (FSMSs), four key components enable
More informationMEAT GRADING AND CERTIFICATION BRANCH QUALITY MANUAL
United States Department of Agriculture Marketing and Regulatory Programs Agricultural Marketing Service Livestock and Seed Program Meat Grading & Certification Branch MGC Instruction 800 May 9, 2005 Page
More informationISO-9001:2000 Quality Management Systems
ISO-9001:2000 Quality Management Systems REQUIREMENTS 10/10/2003 ISO-9001:2000 Requirements 1 Process Based Approach C U S MANAGEMENT RESPONSIBILITY RESOURCE MANAGEMENT C U S T O M Requirements PRODUCT
More informationNABL NATIONAL ACCREDITATION
NABL 160 NABL NATIONAL ACCREDITATION BOARD FOR TESTING AND CALIBRATION LABORATORIES GUIDE for PREPARING A QUALITY MANUAL ISSUE NO. : 05 AMENDMENT NO : 00 ISSUE DATE: 27.06.2012 AMENDMENT DATE: -- Amendment
More informationISO 9001:2008 Quality Management System Requirements (Third Revision)
ISO 9001:2008 Quality Management System Requirements (Third Revision) Contents Page 1 Scope 1 1.1 General. 1 1.2 Application.. 1 2 Normative references.. 1 3 Terms and definitions. 1 4 Quality management
More informationSandoz Private Limited 10/22/15
Sandoz Private Limited 10/22/15 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring, MD 20993 Warning Letter VIA UPS WL: 320-16-01 October 22, 2015
More informationRAC (US) Examination Study Checklist
RAC (US) Examination Study Checklist Instructions: Use this checklist to track your progress when preparing for the RAC (US) certification examination. When you begin your studying, each task statement
More informationGLOBAL AEROSPACE PROCEDURE
1 of 13 1. PURPOSE: This procedure establishes the minimum PPG Aerospace requirements for a Supplier's Quality Plan. These requirements pertain to the documentation and inspection/testing necessary to
More informationGUIDELINES FOR FOOD IMPORT CONTROL SYSTEMS
GUIDELINES FOR FOOD IMPORT CONTROL SYSTEMS SECTION 1 SCOPE CAC/GL 47-2003 1. This document provides a framework for the development and operation of an import control system to protect consumers and facilitate
More informationISO 9001 : 2008 QUALITY MANAGEMENT SYSTEM AUDIT CHECK LIST INTRODUCTION
INTRODUCTION What auditors should look for: the items listed in these headings that the ISO requirement is met that the requirement is met in the manner described in the organization's documentation Page
More informationDeviation and Out of Specification Handling
Deviation and Out of Specification Handling APV Training Course GMP Requirements June,10th to11th 2004 Istanbul, Turkey Dr. Jürgen Mählitz GMP Inspector Fronhof 10 D-86152 Augsburg Germany Dr. Jürgen Mählitz
More informationFood Safety and Quality Management System
Introduction The company has planned, established, documented and implemented a food safety and quality management system for the site, which is maintained in order to continually improve its effectiveness
More informationEffective Root Cause Analysis For Corrective and Preventive Action
Effective Root Cause Analysis For Corrective and Preventive Action Manuel Marco Understanding Key Principles Requirement need or expectation that is stated, generally implied, or obligatory Generally implied
More informationMINIMUM AUTOMOTIVE QUALITY MANAGEMENT SYSTEM REQUIREMENTS FOR SUB-TIER SUPPLIERS
MINIMUM AUTOMOTIVE QUALITY MANAGEMENT SYSTEM REQUIREMENTS FOR SUB-TIER SUPPLIERS CONTENTS 1. CONTROL PLANS 2. PROCESS APPROACH 3. PERFORMANCE 4. INTERNAL AUDITING 5. CONTROL OF NON-CONFORMING PRODUCT 6.
More informationFMC Technologies Measurement Solutions Inc.
Table of Contents 1 Revision History... 4 2 Company... 5 2.1 Introduction... 5 2.2 Quality Policy... 6 2.3 Quality Organization... 6 2.4 Company Processes... 7 3 Scope and Exclusions... 8 3.1 Scope...
More informationAVNET Logistics & EM Americas. Quality Manual
AVNET Logistics & EM Americas Quality Manual Avnet is committed to ensuring customer satisfaction while meeting all customer and applicable legal, statutory and regulatory requirements. This is accomplished
More informationONTIC UK SUPPLIER QUALITY SURVEY
MAIL-IN / ONSITE This report is intended to furnish data relative to the Suppliers capability to control the quality of supplies and services furnished to Ontic UK. Please complete this Survey and return
More informationGuidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More information